Document Detail


Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice.
MedLine Citation:
PMID:  19414400     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Most cancer cells exhibit increased anaerobic glycolysis and use this metabolic pathway for the generation of ATP as a main source of energy. This impaired metabolism of glucose, leading to the secretion of lactic acid even in the presence of oxygen, is named the Warburg effect. Because cancer cells are partly or mainly dependent on such a pathway to generate ATP, inhibition of glycolysis may slow down the proliferation or kill cells. MATERIALS AND METHODS: The effect of 3-Bromopyruvate (3-BrPA) alone or associated to cisplatin on nude mice presenting intraperitoneal carcinomatosis developed after intraperitoneal injection of human mesothelioma cells (MSTO-211H) was investigated. RESULTS: 3-BrPA significantly prolonged survival of animals. Combined with cisplatin, it demonstrated significant benefit on survival whereas cisplatin alone had no or a mild effect. CONCLUSION: 3-BrPA may thus constitute an interesting novel anticancer drug that could be tested in humans.
Authors:
Xiaodong Zhang; Emilie Varin; Mélanie Briand; Stéphane Allouche; Natacha Heutte; Laurent Schwartz; Laurent Poulain; Philippe Icard
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Anticancer research     Volume:  29     ISSN:  0250-7005     ISO Abbreviation:  Anticancer Res.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-05-05     Completed Date:  2009-07-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1443-8     Citation Subset:  IM    
Affiliation:
Anticancer Center Francois BACLESSE, Caen, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cisplatin / pharmacology
Energy Metabolism
Enzyme Inhibitors / pharmacology*
Female
Humans
Mesothelioma / drug therapy*,  pathology
Mice
Mice, Nude
Mitochondria / drug effects,  metabolism
Oxygen Consumption / drug effects*
Peritoneal Neoplasms / drug therapy*,  secondary
Pleural Neoplasms / drug therapy*,  pathology
Pyruvate Dehydrogenase Complex / antagonists & inhibitors
Pyruvates / pharmacology*
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
0/Enzyme Inhibitors; 0/Pyruvate Dehydrogenase Complex; 0/Pyruvates; 1113-59-3/bromopyruvate; 15663-27-1/Cisplatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  (-)-Epigallocatechin gallate induced apoptosis in human adrenal cancer NCI-H295 cells through caspas...
Next Document:  Intracellular glutathione regulates sesquiterpene lactone-induced conversion of autophagy to apoptos...